Board Member
Jazz Pharmaceuticals plc (JAZZ)Equibles does not estimate personal net worth.
Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.
Get JAZZ alertsBruce Cozadd is recorded as Board Member and CEO at Jazz Pharmaceuticals plc (JAZZ). The newest filing on record that lists Bruce Cozadd as Board Member and CEO at Jazz Pharmaceuticals plc (JAZZ) is dated June 14, 2024. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $18,834,836 for Bruce Cozadd in fiscal 2025, including a base salary of $884,789. Disclosed compensation is on record for 9 fiscal years. Bruce Cozadd has spoken on 22 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on August 27, 2025. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jazz Pharmaceuticals plc includes Renee D. Gala (CEO), Renee Gala (CEO, COO and Board Member), Matthew P. Young (CFO) and 7 others.
“Starting on Slide 5, I'd like to congratulate Renee on her unanimous selection by the Jazz Board of Directors as President and CEO. I'm confident Renee is the right leader to build on Jazz's momentum and serve as a catalyst in driving long-term growth.”
“Jazz started the year with strong momentum following a productive 2024, and we're pleased with the meaningful progress we've made across the business in the first quarter of 2025.”
“Thank you for joining us today to discuss Jazz's fourth quarter and full-year 2024 results. I'll start on slide five. I'm very pleased to report that 2024 was another record year for Jazz.”
“We are pleased to report on our progress in the third quarter of 2024, which was headlined by delivering strong growth across our commercial portfolio and advancing our zanidatamab development program.”
“I’ll open with a brief overview of the second quarter and then move to an update on our view of the business moving forward.”
Start not stated–present
Last confirmed June 14, 2024
Start not stated–present
Last confirmed June 14, 2024
Biotechnology · Healthcare
Board Member, CEO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and former CEO | $884,789 | $18,834,836 |
| 2024 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,203,514 | $15,527,464 |
| 2023 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,196,621 | $15,341,235 |
| 2022 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,199,169 | $17,325,618 |
| 2021 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,077,254 | $15,679,311 |
| 2020 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,085,123 | $12,573,300 |
| 2019 | Jazz Pharmaceuticals plc (JAZZ) | Chairperson and CEO | $1,014,415 | $14,713,637 |
| 2018 | Jazz Pharmaceuticals plc (JAZZ) | Chairman and CEO | $979,285 | $11,443,133 |
| 2017 | Jazz Pharmaceuticals plc (JAZZ) | Chairman and CEO | $950,385 | $10,304,610 |
